|
GB9206757D0
(en)
|
1992-03-27 |
1992-05-13 |
Ferring Bv |
Novel peptide receptor ligands
|
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
|
US5628984A
(en)
|
1995-07-31 |
1997-05-13 |
University Of North Carolina At Chapel Hill |
Method of detecting lung disease
|
|
JP2000505068A
(ja)
|
1996-03-13 |
2000-04-25 |
トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア |
補体活性化を阻害する新規ペプチド類
|
|
US6653340B1
(en)
|
1997-06-03 |
2003-11-25 |
Biocryst Pharmaceuticals, Inc. |
Compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
|
|
HUP0101275A3
(en)
|
1998-03-26 |
2002-12-28 |
Japan Tobacco Inc |
Amide derivatives and pharmaceutical compositions containing them as nociceptin antagonists
|
|
WO2000014095A1
(en)
|
1998-09-09 |
2000-03-16 |
Metabasis Therapeutics, Inc. |
Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
|
|
KR20000047461A
(ko)
|
1998-12-29 |
2000-07-25 |
성재갑 |
트롬빈 억제제
|
|
EP1219611A4
(en)
|
1999-09-03 |
2003-03-19 |
Ajinomoto Kk |
NEW PROCESSES FOR THE PRODUCTION OF OXAZEPINE DERIVATIVES
|
|
US7528165B2
(en)
|
2001-12-13 |
2009-05-05 |
National Health Research Institutes |
Indole compounds
|
|
ITMI20021527A1
(it)
|
2002-07-11 |
2004-01-12 |
Consiglio Nazionale Ricerche |
Anticorpi anti componente c5 del complemento e loro uso
|
|
US20060100431A1
(en)
|
2002-07-16 |
2006-05-11 |
Amura Therapeutics Limited |
Biologically active compounds
|
|
US9415102B2
(en)
|
2002-09-06 |
2016-08-16 |
Alexion Pharmaceuticals, Inc. |
High concentration formulations of anti-C5 antibodies
|
|
DK1549333T3
(da)
|
2002-09-20 |
2012-01-16 |
Univ Pennsylvania |
Compstatinanaloge med forbedret aktivitet
|
|
FR2845382A1
(fr)
|
2002-10-02 |
2004-04-09 |
Sanofi Synthelabo |
Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
|
|
EP1567487A4
(en)
|
2002-11-15 |
2005-11-16 |
Bristol Myers Squibb Co |
OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
|
|
AU2003902946A0
(en)
|
2003-06-12 |
2003-06-26 |
Fujisawa Pharmaceutical Co., Ltd. |
Dpp-iv inhibitor
|
|
US7482376B2
(en)
|
2003-07-03 |
2009-01-27 |
3-Dimensional Pharmaceuticals, Inc. |
Conjugated complement cascade inhibitors
|
|
DK1713503T3
(da)
|
2004-02-10 |
2013-11-04 |
Univ Colorado Regents |
Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
|
|
ES2530056T3
(es)
|
2004-03-24 |
2015-02-26 |
Shire Orphan Therapies Gmbh |
Nuevos compuestos para la inhibición de la angiogénesis y su uso
|
|
US7417063B2
(en)
|
2004-04-13 |
2008-08-26 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles useful as serine protease inhibitors
|
|
EP1814576A2
(en)
|
2004-07-20 |
2007-08-08 |
Critical Therapeutics, Inc. |
Combination therapies of hmgb and complement inhibitors against inflammation
|
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
|
CN106188239B
(zh)
|
2005-11-28 |
2020-01-07 |
宾夕法尼亚州大学理事会 |
有效的坎普他汀类似物
|
|
JP2009519342A
(ja)
|
2005-12-12 |
2009-05-14 |
ジェネラブズ テクノロジーズ インコーポレーティッド |
Ｎ−（６員芳香環）−アミド抗ウイルス化合物
|
|
ES2965283T3
(es)
|
2006-03-15 |
2024-05-28 |
Alexion Pharma Inc |
Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento
|
|
JPWO2008047831A1
(ja)
|
2006-10-17 |
2010-02-25 |
協和発酵キリン株式会社 |
Ｊａｋ阻害剤
|
|
US8193237B2
(en)
|
2007-01-15 |
2012-06-05 |
Santen Pharmaceutical Co., Ltd. |
Indole derivative having IκB kinase β inhibitory activity
|
|
AU2008214359B2
(en)
|
2007-02-05 |
2014-01-16 |
Apellis Pharmaceuticals, Inc. |
Local complement inhibition for treatment of complement-mediated disorders
|
|
US8524716B2
(en)
|
2007-12-24 |
2013-09-03 |
Janssen R&D Ireland |
Macrocyclic indoles as hepatitis C virus inhibitors
|
|
WO2009091826A2
(en)
|
2008-01-14 |
2009-07-23 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
|
|
PY09026846A
(es)
|
2008-08-05 |
2015-09-01 |
Novartis Ag |
Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
|
|
GB2469471B
(en)
|
2009-04-14 |
2015-01-14 |
Skype |
Optimising communications
|
|
CN102458438A
(zh)
|
2009-05-01 |
2012-05-16 |
宾夕法尼亚州大学理事会 |
具有肽骨架和c-末端修饰的经修饰补体抑素
|
|
US9291622B2
(en)
|
2009-05-21 |
2016-03-22 |
Apellis Pharmaceuticals, Inc. |
Complement assays and uses thereof
|
|
EP2490026A4
(en)
|
2009-10-16 |
2013-08-21 |
Mochida Pharm Co Ltd |
MARKER ASSOCIATED WITH NON ALCOHOLIC STÉATOHÉPATITE
|
|
EP2496259B1
(en)
|
2009-11-05 |
2017-02-22 |
Alexion Pharmaceuticals, Inc. |
Treatment of paroxysmal nocturnal hemoglobinuria
|
|
RS61281B1
(sr)
|
2009-12-31 |
2021-02-26 |
Hutchison Medipharma Ltd |
Sintetički intermedijer koristan u pripremi triazolopiridinskih c-met inhibitora
|
|
AU2011239966B2
(en)
|
2010-04-16 |
2014-05-08 |
Ac Immune S.A. |
Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
|
|
US9421240B2
(en)
|
2010-06-22 |
2016-08-23 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogs for treatment of neuropathic pain
|
|
US20130324482A1
(en)
|
2010-07-09 |
2013-12-05 |
Apellis Pharmaceuticals, Inc. |
Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
|
|
KR20140027090A
(ko)
|
2011-01-04 |
2014-03-06 |
노파르티스 아게 |
연령-관련 황반 변성 (amd)의 치료에 유용한 인돌 화합물 또는 그의 유사체
|
|
CA2835627C
(en)
|
2011-05-11 |
2023-01-10 |
Apellis Pharmaceuticals, Inc. |
Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
|
|
KR101931311B1
(ko)
|
2011-05-27 |
2018-12-20 |
아칠리온 파르마세우티칼스 인코포레이티드 |
Ｈｃｖ 감염 치료에 유용한 치환된 앨리팬, 시클로팬, 헤테라팬, 헤테로팬, 헤테로-헤테라팬 및 메탈로센
|
|
CA2877474A1
(en)
|
2011-06-20 |
2012-12-27 |
Myrexis, Inc. |
Compounds and therapeutic uses thereof
|
|
EP2723361B1
(en)
|
2011-06-22 |
2019-10-30 |
Apellis Pharmaceuticals, Inc. |
Methods of treating chronic disorders with complement inhibitors
|
|
US20130035392A1
(en)
|
2011-08-01 |
2013-02-07 |
Mcgeer Patrick L |
Selective inhibition of the membrane attack complex of complement and C3 convertase by low molecular weight components of the aurin tricarboxylic acid synthetic complex
|
|
CA2847862C
(en)
|
2011-09-07 |
2021-01-12 |
The Trustees Of The University Of Pennsylvania |
Compstatin analogs with improved pharmacokinetic properties
|
|
CN111700880A
(zh)
|
2012-05-03 |
2020-09-25 |
卡拉制药公司 |
显示提高的粘膜转移的药物纳米粒子
|
|
US9056874B2
(en)
|
2012-05-04 |
2015-06-16 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
|
JP6180514B2
(ja)
|
2012-05-04 |
2017-08-16 |
ノバルティス アーゲー |
補体経路モジュレーターおよびその使用
|
|
EP2861246B1
(en)
|
2012-06-18 |
2021-01-20 |
Omeros Corporation |
Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders
|
|
AU2013277154A1
(en)
|
2012-06-20 |
2014-12-18 |
Jonathan E. Grob |
Complement pathway modulators and uses thereof
|
|
US9579360B2
(en)
|
2012-06-20 |
2017-02-28 |
The Trustees Of The University Of Pennsylvania |
Methods of treating or preventing periodontitis and diseases associated with periodontitis
|
|
JP6273274B2
(ja)
|
2012-06-28 |
2018-01-31 |
ノバルティス アーゲー |
補体経路モジュレーターおよびその使用
|
|
EP2867229B1
(en)
|
2012-06-28 |
2017-07-26 |
Novartis AG |
Pyrrolidine derivatives and their use as complement pathway modulators
|
|
EP2867225B1
(en)
|
2012-06-28 |
2017-08-09 |
Novartis AG |
Pyrrolidine derivatives and their use as complement pathway modulators
|
|
WO2014002053A1
(en)
|
2012-06-28 |
2014-01-03 |
Novartis Ag |
Pyrrolidine derivatives and their use as complement pathway modulators
|
|
US20150191462A1
(en)
|
2012-06-28 |
2015-07-09 |
Novartis Ag |
Pyrrolidine derivatives and their use as complement pathway modulators
|
|
ES2712190T3
(es)
|
2012-06-28 |
2019-05-09 |
Novartis Ag |
Moduladores de la vía del complemento y sus usos
|
|
ITMI20121156A1
(it)
|
2012-06-29 |
2013-12-30 |
Consiglio Nazionale Ricerche |
Metodo di elaborazione di immagini di tomografia a coerenza ottica
|
|
WO2014005150A1
(en)
|
2012-06-29 |
2014-01-03 |
Novartis Ag |
Crystalline forms of l-(2-((lr,3s,5r)-3-( (2 -fluoro-3 - (trifluoromethoxy) phenyl) carbamoyl) - 2 -azabicycl o [3.1.0] hexan- 2 -yl) - 2 -oxoethyl) - 5 -methyl - 1h - pyrazolo [3, 4 -c] pyridine - 3 - carboxami de and salts thereof
|
|
WO2014002059A1
(en)
|
2012-06-29 |
2014-01-03 |
Novartis Ag |
CRYSTALLINE FORMS OF 1-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazolo[3,4-c]pyridine-3-carboxamide
|
|
EP2872503B1
(en)
|
2012-07-12 |
2018-06-20 |
Novartis AG |
Complement pathway modulators and uses thereof
|
|
MX2015002954A
(es)
|
2012-09-10 |
2015-06-05 |
Hoffmann La Roche |
Nuevas 6-aminoacido-heteroarilhidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b.
|
|
US20160194359A1
(en)
|
2012-11-15 |
2016-07-07 |
Apellis Pharmaceuticals, Inc. |
Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
|
|
EP3929206A1
(en)
|
2012-11-15 |
2021-12-29 |
Apellis Pharmaceuticals, Inc. |
Long-acting compstatin analogs and related compositions and methods
|
|
US9773428B2
(en)
|
2012-12-11 |
2017-09-26 |
Fluidity Software, Inc. |
Computerized system and method for teaching, learning, and assessing step by step solutions to stem problems
|
|
CA2899034A1
(en)
|
2013-01-23 |
2014-07-31 |
Musc Foundation For Research Development |
Targeting constructs based on natural antibodies and uses thereof
|
|
CN105229003B
(zh)
|
2013-03-14 |
2017-03-15 |
诺华股份有限公司 |
作为补体因子b抑制剂用于治疗眼科疾病的2‑(1h‑吲哚‑4‑基甲基)‑3h‑咪唑并[4,5‑b]吡啶‑6‑甲腈衍生物
|
|
US10308687B2
(en)
|
2013-03-15 |
2019-06-04 |
Apellis Pharmaceuticals, Inc. |
Cell-penetrating compstatin analogs and uses thereof
|
|
JO3425B1
(ar)
|
2013-07-15 |
2019-10-20 |
Novartis Ag |
مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
|
|
KR20160036568A
(ko)
|
2013-07-18 |
2016-04-04 |
노파르티스 아게 |
보체 인자 d 억제제로서의 아미노메틸-비아릴 유도체 및 그의 용도
|
|
JP2016169161A
(ja)
|
2013-07-19 |
2016-09-23 |
大日本住友製薬株式会社 |
新規イミダゾピリジン化合物
|
|
SI3011345T1
(sl)
|
2013-08-07 |
2017-12-29 |
Alexion Pharmaceuticals, Inc. |
Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
|
|
WO2015054569A1
(en)
|
2013-10-10 |
2015-04-16 |
Viropharma Holdings Limited |
Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
|
|
CN105849090A
(zh)
|
2013-10-30 |
2016-08-10 |
诺华股份有限公司 |
2-苄基-苯并咪唑补体因子b抑制剂及其用途
|
|
KR20160118368A
(ko)
|
2014-02-25 |
2016-10-11 |
아칠리온 파르마세우티칼스 인코포레이티드 |
보체 매개된 장애의 치료를 위한 에터 화합물
|
|
WO2016088082A1
(en)
|
2014-12-05 |
2016-06-09 |
Novartis Ag |
Amidomethyl-biaryl derivatives complement factor d inhibitors and uses thereof
|
|
AU2016301196B2
(en)
|
2015-08-06 |
2022-09-08 |
Dana-Farber Cancer Institute, Inc. |
Tunable endogenous protein degradation
|
|
AR105809A1
(es)
|
2015-08-26 |
2017-11-08 |
Achillion Pharmaceuticals Inc |
Compuestos para el tratamiento de trastornos médicos
|
|
WO2017035405A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amino compounds for treatment of immune and inflammatory disorders
|
|
WO2017035361A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Disubstituted compounds for the treatment of medical disorders
|
|
WO2017035417A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Phosphonate compounds for treatment of immune and inflammatory disorders
|
|
WO2017035415A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Alkyne compounds for treatment of immune and inflammatory disorders
|
|
WO2017035418A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Disubstituted compounds for treatment of immune and inflammatory disorders
|
|
WO2017035411A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Ether compounds for treatment of immune and inflammatory disorders
|
|
WO2017035362A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
|
|
US10385097B2
(en)
|
2015-08-26 |
2019-08-20 |
Achillion Pharmaceuticals, Inc. |
Ether compounds for treatment of medical disorders
|
|
AR105808A1
(es)
|
2015-08-26 |
2017-11-08 |
Achillion Pharmaceuticals Inc |
Compuestos de amida para el tratamiento de trastornos médicos
|
|
AR106018A1
(es)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
|
|
WO2017035401A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amide compounds for treatment of immune and inflammatory disorders
|
|
WO2017035351A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amino compounds for treatment of medical disorders
|
|
WO2017035413A2
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders
|
|
EP3340982B1
(en)
|
2015-08-26 |
2021-12-15 |
Achillion Pharmaceuticals, Inc. |
Compounds for treatment of immune and inflammatory disorders
|
|
WO2017035348A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Alkyne compounds for treatment of medical disorders
|
|
WO2017035357A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Phosphonate compounds for treatment of medical disorders
|
|
WO2017035352A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Carbamate, ester, and ketone compounds for treatment of medical disorders
|
|
EP3340983B1
(en)
|
2015-08-26 |
2023-10-04 |
Achillion Pharmaceuticals, Inc. |
Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
|
|
CN109310675A
(zh)
|
2015-12-11 |
2019-02-05 |
莱福斯希医药公司 |
治疗性抑制化合物
|
|
MX2022006069A
(es)
|
2016-01-14 |
2023-01-12 |
Chemocentryx Inc |
Metodo para tratar glomerulopatia c3.
|
|
EP3405577B8
(en)
|
2016-01-20 |
2023-02-15 |
396419 B.C. Ltd. |
Compositions and methods for inhibiting factor d
|
|
TWI747873B
(zh)
|
2016-02-01 |
2021-12-01 |
美商百歐克斯製藥公司 |
苯并吡唑化合物及其類似物
|
|
CN109414441A
(zh)
|
2016-06-27 |
2019-03-01 |
艾其林医药公司 |
治疗医学障碍的喹唑啉和吲哚化合物
|
|
JOP20170154B1
(ar)
|
2016-08-01 |
2023-03-28 |
Omeros Corp |
تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
|
|
KR102632860B1
(ko)
*
|
2017-03-01 |
2024-02-02 |
아칠리온 파르마세우티칼스 인코포레이티드 |
의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물
|
|
WO2018160892A1
(en)
|
2017-03-01 |
2018-09-07 |
Achillion Pharmaceuticals, Inc. |
Macrocyclic compounds for treatment of medical disorders
|
|
WO2018160891A1
(en)
|
2017-03-01 |
2018-09-07 |
Achillion Pharmaceutical, Inc. |
Pharmaceutical compounds for treatment of medical disorders
|
|
EP3661493A4
(en)
|
2017-08-02 |
2021-04-14 |
Achillion Pharmaceuticals, Inc. |
THERAPY PLANS FOR TREATMENT OF PAROXYSMALER NIGHTLY HEMOGLOBINURIA
|
|
US20200262897A1
(en)
|
2017-10-04 |
2020-08-20 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis
|
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
|
EP3856164B1
(en)
|
2018-09-25 |
2024-08-07 |
Achillion Pharmaceuticals, Inc. |
Morphic forms of complement factor d inhibitors
|
|
WO2020109343A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Combination therapy for treatment of macular degeneration
|
|
BR112021011727A2
(pt)
|
2018-12-17 |
2021-08-31 |
Achillion Pharmaceuticals, Inc |
Dosagem direcionada para o tratamento de distúrbios mediados do complemento
|